Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
... be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome.
hypokalemia or hypomagnesemia must be corrected prior to TASIGNA administration and ...
QT prolongation
Tasigna prolongs the QT interval. Correct
hypokalemia or hypomagnesemia prior to administration and monitor periodically. Avoid ...
MULTAQ(R) (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States
... MULTAQ treatment initiation. The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation.
hypokalemia and hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. Potassium levels should be maintained in the normal ...
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
... Multaq(R) treatment initiation. The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation.
hypokalemia and hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. Potassium levels should be maintained in the normal ...
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
... more common among Vaprisol-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%),
hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20mg/day and 40mg/day, respectively.(1 ) For full prescribing ...
GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
... prolongs the QT interval in some patients. TYKERB should be administered with caution to patients who have or may develop prolongation of QTc.
hypokalemia or hypomagnesemia should be corrected prior to TYKERB administration. Baseline and on-treatment electrocardiograms with QT measurement should be ...
Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical
... Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord.
hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely with vitamin B12.
Side effects thought to be related to ...
Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
... prolongs the QT interval in some patients. TYKERB should be administered with caution to patients who have or may develop prolongation of QTc.
hypokalemia or hypomagnesemia should be corrected prior to TYKERB administration. Baseline and on-treatment electrocardiograms with QT measurement should be ...
ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia
... more common among Vaprisol-treated patients
(3%) than among placebo-treated patients (0%). Other common adverse
reactions were headaches (8%, 10%),
hypokalemia (22%, 10%), orthostatic
hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20mg/day and
40mg/day, respectively. For more information about ...
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
... (14% vs 10%), pain in extremity (14% vs 9%), abdominal
pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%),
bronchitis (13% vs 8%),
hypokalemia (13% vs 7%), hypertension (13% vs 7%),
abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11%
vs 7%), nasopharyngitis (11% vs 8%), ...
Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products
... and intestinal cramps, which are usually transient.
Excessive dosage can lead to diarrhea with potential complications such as
loss of fluids,
hypokalemia and hypernatremia. Nausea and vomiting have
been reported. Use with caution in diabetics. Kristalose(R) is
contraindicated in patients who require a ...
Hypokalemia in Medical Technology
Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
... in patients with
hypokalemia, hypomagnesemia, or long QT syndrome.
hypokalemia or
hypomagnesemia must be corrected prior to TASIGNA administration ...
QT prolongation
Tasigna prolongs the QT interval. Correct
hypokalemia or hypomagnesemia prior to administration and monitor periodically. Avoid ...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
... be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome.
hypokalemia or hypomagnesemia must be corrected prior to Tasigna administration and ...
QT prolongation
Tasigna prolongs the QT interval. Correct
hypokalemia or hypomagnesemia prior to administration and monitor periodically. Avoid ...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13% vs 8%),
hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), ...
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
... (14% vs 10%), pain in
extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%),
herpes zoster (13% vs 4%), bronchitis (13% vs 8%),
hypokalemia (13% vs 7%),
hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12%
vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), ...
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
... (14% vs 10%), pain in
extremity (14% vs 9%), abdominal pain (14% vs 7%), paresthesia (13% vs 4%),
herpes zoster (13% vs 4%), bronchitis (13% vs 8%),
hypokalemia (13% vs 7%),
hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12%
vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), ...
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
... (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14%
vs 7%), paresthesia (13% vs 4%), herpes zoster (13% vs 4%), bronchitis (13%
vs 8%),
hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain
upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%),
nasopharyngitis (11% vs 8%), ...
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
... have been reported in
patients receiving nilotinib. Tasigna should not be used in patients with
hypokalemia, hypomagnesemia, or long QT syndrome.
hypokalemia or
hypomagnesemia must be corrected prior to Tasigna administration and should
be periodically monitored. Drugs known to prolong the QT interval ...
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
... (12.7%) and malaise (10.9%). The most common adverse reactions by
IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%)
and
hypokalemia (31.3%).
Because treatment with Vidaza is associated with neutropenia and
thrombocytopenia, complete blood counts should be performed as needed ...
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
... (12.7%) and malaise (10.9%). The most common adverse reactions by
IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%)
and
hypokalemia (31.3%).
Because treatment with Vidaza is associated with neutropenia and
thrombocytopenia, complete blood counts should be performed as needed ...
MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
... (12.7%) and malaise (10.9%). The most common adverse reactions by
IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%)
and
hypokalemia (31.3%).
Because treatment with Vidaza is associated with neutropenia and
thrombocytopenia, complete blood counts should be performed as needed ...
Hypokalemia in Medical Definition
Pathology
... , Lactic ) - Alkalosis ( Metabolic , Respiratory ) - Mixed disorder of acid-base balance - H 2 O Dehydration / Hypervolemia - K +
hypokalemia / Hyperkalemia - Cl − Hyperchloremia / Hypochloremia
Purine and pyrimidine
Hyperuricemia - Lesch-Nyhan syndrome - Xanthinuria ...
Hypokalemia in Medical Dictionary
Hypokalemia
...
hypokalemia - Abnormal decrease in blood potassium ... of 3.8 to 5.0 milliequivalents per liter.
hypokalemia Definition:
hypokalemia means low serum potassium (low blood ...
Arrhythmias
... of the heart ( cardiac arrhythmias ). Low serum potassium (
hypokalemia ) occurs when serum potassium falls below 3.0 mM. Various ... should be in the range of 3.8 to 5.0 milliequivalents per liter.
hypokalemia can occur secondary to a drug side effect, vomiting , or excessive ...
Hyperkalemia
... Detect potassium levels in the blood that are too low (
hypokalemia ) or too high ( hyperkalemia ). This may be done for people being treated ... potassium in the blood instead of low levels. Either low potassium (
hypokalemia ) or high potassium ( hyperkalemia ) ... ...
Potassium
... treatment of potassium deficiency , treatment or prevention of
hypokalemia . Product is bioequivalent to Key Pharmaceuticals' K-Dur 20. Field: ... immunosuppressant drugs may be given to reduce the inflammation .
hypokalemia - Abnormal decrease in blood potassium concentration. Can result in ...
Aldosterone
... tract is the digestive tract. BARTTER'S SYNDROME - A clinical syndrome characterized by enlargement of certain kidney cells, alkalosis ,
hypokalemia , and increased production of the hormone aldosterone . Common in children and may be seen in dwarfism . Ad renal cortexThe outer tissue of ...
Alkalosis
... tranquilizers), ... BARTTER'S SYNDROME - A clinical syndrome characterized by enlargement of certain kidney cells, alkalosis ,
hypokalemia , and increased production of the hormone aldosterone . Common in children and may be seen in dwarfism . Environmental Causes Incorrect Water ...
Diarrhea
... from the nether regions, smell something awful and feel something wet all over your hand . OK, a diaper blowout, you think. Watery diarrhea
hypokalemia (low blood potassium ), which can cause leg cramps Low acid in the stomach Dehydration Abdominal pain and cramp ing Weight loss ...
Digit
... and anti tumor medicines ( chemotherapy ) a high level of calcium in the blood ( hypercalcemia ) a low level of potassium in the blood (
hypokalemia ) alcohol abuse viral hepatitis (an infection of the liver ) ... Digit al photographs were taken of the participants and their work. The ...
Hypercalcemia
... and anti tumor medicines ( chemotherapy ) a high level of calcium in the blood ( hypercalcemia ) a low level of potassium in the blood (
hypokalemia ) alcohol abuse viral hepatitis (an infection of the liver ) ... with multiple myeloma and the treatment of patients with documented ...
Leg cramps
... cramps ; giving description, causes, treatment , and prevention of this extremely common condition. Source:MedicineNet ... Watery diarrhea
hypokalemia (low blood potassium ), which can cause leg cramps Low acid in the stomach Dehydration Abdominal pain and cramp ing Weight loss ...
More>>
Hypokalemia in Biological Technology
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
... be used in patients with
hypokalemia, hypomagnesemia, or long QT syndrome.
hypokalemia or
hypomagnesemia must be corrected prior to Tasigna administration and ... reduction.
QT prolongation
Tasigna prolongs the QT interval. Correct
hypokalemia or hypomagnesemia
prior to administration and monitor periodically. Avoid ...
FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
... more common among
Vaprisol-treated patients (3%) than among placebo-treated patients (0%).
Other common adverse reactions were headaches (8%, 10%),
hypokalemia (22%,
10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol
20mg/day and 40mg/day, respectively. For full prescribing ...
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
... (12.7%) and malaise (10.9%). The most common adverse reactions by
IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%)
and
hypokalemia (31.3%).
Because treatment with Vidaza is associated with neutropenia and
thrombocytopenia, complete blood counts should be performed as needed ...
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
... and patients taking anti-
arrhythmic drugs, other medicinal products that lead to QT prolongation, or
cumulative high-dose anthracycline therapy.
hypokalemia or hypomagnesemia
should be corrected prior to SPRYCEL administration. Drug Interactions: Dasatinib is a CYP3A4 substrate. Drugs that may increase ...
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
... and associated encephalopathy in patients with deficiencies
in enzymes of the urea cycle. The most common adverse reactions are
vomiting (9%),
hypokalemia (7%), hyperglycemia (7%), convulsions (6%), and
mental impairments (6%). Do not administer to patients with known
hypersensitivity to sodium ...